Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,584,056
  • Shares Outstanding, K 165,720
  • Annual Sales, $ 2,225 M
  • Annual Income, $ 272,000 K
  • 60-Month Beta 0.22
  • Price/Sales 2.97
  • Price/Cash Flow 14.79
  • Price/Book 3.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.41
  • Growth Rate Est. (year over year) +243,558.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.29 +6.49%
on 10/14/19
40.88 -2.86%
on 11/07/19
+2.37 (+6.35%)
since 10/11/19
3-Month
34.67 +14.54%
on 08/28/19
40.88 -2.86%
on 11/07/19
+3.47 (+9.58%)
since 08/12/19
52-Week
33.54 +18.40%
on 11/13/18
42.82 -7.26%
on 05/07/19
+6.29 (+18.82%)
since 11/12/18

Most Recent Stories

More News
New Strong Sell Stocks for November 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

PLT : 25.28 (-0.75%)
BXC : 14.51 (-6.21%)
RDY : 39.75 (+0.05%)
ASM : 0.49 (-2.00%)
EAF : 13.77 (+4.08%)
Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

ABBV : 86.43 (+0.90%)
GSK : 44.51 (+0.56%)
MRK : 84.13 (+1.02%)
RDY : 39.75 (+0.05%)
Dr. Reddy's Q2 & H1 FY20 Financial Results

Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International...

RDY : 39.75 (+0.05%)
Dr. Reddy's Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries, together referred to as "Dr. Reddy's") confirms it had initiated a voluntary nationwide recall on October...

RDY : 39.75 (+0.05%)
Dr. Reddy's to release Q2 FY 20 results on November 1, 2019

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2019 on Friday, November 1, 2019 after the Board Meeting.

RDY : 39.75 (+0.05%)
Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

PFE : 36.98 (+0.14%)
MYL : 17.53 (+1.68%)
TEVA : 9.61 (+3.00%)
RDY : 39.75 (+0.05%)
The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

WNS : 62.10 (+0.03%)
RDY : 39.75 (+0.05%)
AZRE : 13.19 (+0.30%)
BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%

BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

RDY : 39.75 (+0.05%)
BBIO : 27.97 (+4.56%)
Foamix Initiates Phase II Study on Acne Combination Foam

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

FOMX : 3.40 (-2.30%)
EVOK : 0.92 (+4.55%)
RDY : 39.75 (+0.05%)
BHC : 27.01 (+1.85%)
Is it Apt to Foray Into the Indian Stock Market?: An Analysis

The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%....

WNS : 62.10 (+0.03%)
RDY : 39.75 (+0.05%)
AZRE : 13.19 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade RDY with:

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

2nd Resistance Point 40.27
1st Resistance Point 40.00
Last Price 39.75
1st Support Level 39.48
2nd Support Level 39.23

See More

52-Week High 42.82
Last Price 39.75
Fibonacci 61.8% 39.28
Fibonacci 50% 38.18
Fibonacci 38.2% 37.08
52-Week Low 33.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar